Clinical Trial Update: An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly [Phase 2]

View source ↗

Summary

An extension study reports long-term safety and efficacy data for pasireotide in acromegaly participants (Phase 2), completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Pasireotide (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 2 | Status: COMPLETED | Results posted: 2021-06-02